EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
Andrés Felipe CardonaCamila Ordóñez-ReyesAlejandro Ruíz-PatiñoJuan Esteban Garcia-RobledoLucia Zatarain BarronGonzalo RecondoLeonardo RojasLuis Corrales-RodríguezClaudio Marcelo MartinFeliciano BarrónCarolina Sotelo-RodríguezJuly RodríguezLuisa RicaurteChristian C RolfoJenny ÁvilaDiana MayorgaPilar ArchilaJorge OteroLuis MasMaritza BermudezTatiana GamezHernán CarranzaCarlos VargasRafael RosellArrieta OscarPublished in: JCO precision oncology (2022)
EGFR-TKIs plus Bev conferred a significantly higher ORR and PFS in advanced NSCLC patients with EGFR mutation and BIMdel. Further prospective studies are needed to validate these findings.